Literature DB >> 2181524

The use of kinetic-dynamic interactions in the evaluation of drugs.

D B Campbell1.   

Abstract

Deterred by the complexity of the mathematics, pharmacologists and clinical pharmacologists have only recently appreciated the usefulness of pharmacokinetics in drug development. Now unfortunately, although the vernacular of the science is known, often the meaning behind the words is lost. It is often assumed that drug levels are linearly related to drug action. Frequently they are not. This review shows, with reference to psychotropic drugs, how, in simple terms, it is possible to relate pharmacokinetics with pharmacodynamics, and how such relationships may provide a greater insight into drug activity and enhance drug development. Assuming that an equilibrium exists between the drug in plasma levels, and at the site of action, the same Michaelis-Menten equations used to relate effect to drug receptor binding can be used for drug level-dynamic interactions. A number of these relationships have been published and are discussed in terms of their derivation and their limitations. The graphical and computerised methods to create complete Emax curves are described and how the parameters of maximal effect, potency, variability and slope can be measured. When the drug is not in equilibrium with its site of action, hysteresis occurs and drug levels are out of phase with activity. Anticlockwise hysteresis, that is, activity increasing with time for a given drug level, can be caused by uptake into an active site, active metabolites, cascade activity, and sensitisation whilst clockwise hysteresis, in which activity decreases with time, can be caused by tolerance, active antagonistic metabolites, learning effects and feedback regulation. Attempts to relate simultaneously kinetics and dynamics by Link models can be difficult and not always necessary. It is assumed in therapeutic drug monitoring that individuals will show the same response for a given drug level. On the contrary, differences in individual subject sensitivity to drugs measured by kinetic-dynamic relationships may provide a greater understanding of the disease itself.

Mesh:

Substances:

Year:  1990        PMID: 2181524     DOI: 10.1007/BF02243994

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  97 in total

1.  Response optimization of drug dosage: antiarrhythmic studies with tocainide.

Authors:  P J Meffin; R A Winkle; T F Blaschke; J Fitzgerald; D C Harrison; S R Harapat; P A Bell
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

Review 2.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

3.  Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers.

Authors:  W B Taylor; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

Review 4.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 5.  Pharmacokinetic studies: their role in determining therapeutic efficacy of agents designed to prevent sudden death.

Authors:  D G Shand; E L Pritchett; S C Hammill; W W Stargel; G S Wagner
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

Review 6.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

7.  Comparison of the time course of the anorectic effect of fenfluramine and amphetamine with drug levels in blood.

Authors:  J E Blundell; D B Campbell; M Lesham; R Tozer
Journal:  J Pharm Pharmacol       Date:  1975-03       Impact factor: 3.765

8.  Relation between time courses of pharmacological effects and of plasma levels of camazepam and its active metabolites in rats.

Authors:  A Morino; M Sugiyama
Journal:  J Pharmacobiodyn       Date:  1985-08

9.  Pharmacodynamics of triazolam after intravenous administration.

Authors:  R B Smith; P D Kroboth; P D Varner
Journal:  J Clin Pharmacol       Date:  1987-12       Impact factor: 3.126

10.  Pharmacodynamic modeling of thiopental anesthesia.

Authors:  D R Stanski; R J Hudson; T D Homer; L J Saidman; E Meathe
Journal:  J Pharmacokinet Biopharm       Date:  1984-04
View more
  16 in total

1.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

Review 2.  The use of population pharmacokinetics in drug development.

Authors:  S Vozeh; J L Steimer; M Rowland; P Morselli; F Mentre; L P Balant; L Aarons
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.

Authors:  B G Reigner; P E Williams; I H Patel; J L Steimer; C Peck; P van Brummelen
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

4.  Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis.

Authors:  Cristian Salinas; David Weinzimmer; Graham Searle; David Labaree; Jim Ropchan; Yiyun Huang; Eugenii A Rabiner; Richard E Carson; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2013-02-06       Impact factor: 6.200

5.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 6.  The use of toxicokinetics for the safety assessment of drugs acting in the brain.

Authors:  D B Campbell
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

Review 7.  Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.

Authors:  A Van Peer; E Snoeck; M L Huang; J Heykants
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

Review 8.  Pharmacokinetic and pharmacodynamic data and models in clinical trials.

Authors:  J L Steimer; M E Ebelin; J Van Bree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

9.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Authors:  L A Jopling; G F Watt; S Fisher; H Birch; S Coggon; M I Christie
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 10.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.